Industry Asks CMS Not To Tread On FDA's Medtech Safety Authority
CMS should leave questions regarding medtech safety to FDA rather than re-examine them in coverage with evidence development studies, according to physicians and industry stakeholders.
CMS should leave questions regarding medtech safety to FDA rather than re-examine them in coverage with evidence development studies, according to physicians and industry stakeholders.